biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
17:34 Unusually low or high hemoglobin on routine blood tests tied to dementia✦17:33 Three-drug mix kept advanced melanoma in check far longer in a trial✦05:37 Some breast cancer patients skipped chemo; 92% stayed disease-free 5 years✦05:32 Blood test flagged Alzheimer's-linked memory decline up to 10 years ahead✦11:34 FDA gives quick approval to DNA treatment to cut repeat airway surgeries✦05:38 Testosterone showed no clear memory boost after menopause, review finds✦05:36 Scalp gel that aims to wake hair follicles will be tested in 200 women✦05:33 Lilly's experimental weight-loss shot cut sleep apnea breathing pauses✦17:34 Unusually low or high hemoglobin on routine blood tests tied to dementia✦17:33 Three-drug mix kept advanced melanoma in check far longer in a trial✦05:37 Some breast cancer patients skipped chemo; 92% stayed disease-free 5 years✦05:32 Blood test flagged Alzheimer's-linked memory decline up to 10 years ahead✦11:34 FDA gives quick approval to DNA treatment to cut repeat airway surgeries✦05:38 Testosterone showed no clear memory boost after menopause, review finds✦05:36 Scalp gel that aims to wake hair follicles will be tested in 200 women✦05:33 Lilly's experimental weight-loss shot cut sleep apnea breathing pauses
← People to follow
DS
PERSON TO FOLLOW

Dirk Schadendorf

Director, Dermatology and West German Cancer Center, University Hospit

Professor of dermatology and oncology at University Hospital Essen in Germany. He presented the final results of the STARBOARD melanoma trial at the 2026 European Society for Medical Oncology Congress.

melanomaimmunotherapytargeted therapyskin cancer

WHAT TO WATCHWhether longer follow-up of STARBOARD shows a clear survival benefit and how guidelines respond.

ON THE WIRE

Every story about Dirk’s work.

Profile sources

  1. 1
    Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma | CancerNetwork cancernetwork.com